Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 29:11:856.
doi: 10.3389/fphar.2020.00856. eCollection 2020.

An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

Giuseppe Terrazzano  1   2 , Valentina Rubino  1 , Anna Teresa Palatucci  2 , Angela Giovazzino  2 , Flavia Carriero  2 , Giuseppina Ruggiero  2
Affiliations

An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

Giuseppe Terrazzano et al. Front Pharmacol. .
No abstract available

Keywords: COVID-19; Everolimus; hyper-activation; immune-regulation; mTOR.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The hypothesis of a therapy using mTOR inhibitors (Everolimus) in COVID-19. The critical phases of COVID-19 show pathophysiological aspects resembling a sort of immune response hypersensitivity, mediated by exacerbated immune mechanism and cytokine storm. mTOR inhibition (i.e., by Everolimus) could act in reducing SARS-CoV2 replication (A), in inhibiting the cytokine storm dependent on the hyper-activated-STAT3 pathway (B), in contrasting Treg down-regulation, and in reducing conventional hyper-reactive T cells (C) in COVID-19. Current step-use of Tocilizumab, Hydrochloroquine, Heparin, and Steroids is reported in the figure.
See this image and copyright information in PMC

References

    1. Albert S., Serova M., Dreyer C., Sablin M. P., Faivre S., Raymond E. (2010). New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert. Opin. Investig. Drugs 19, 919–930. 10.1517/13543784.2010.49912 - DOI - PubMed
    1. Askanase A. D., Khalili L., Buyon J. P. (2020). Thoughts on COVID-19 and autoimmune diseases. Lupus Sci. Med. 3, 7. 10.1136/lupus-2020-000396 - DOI - PMC - PubMed
    1. Aziz M., Fatima R., Assaly R. (2020). Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis. J. Med. Virol. 10.1002/jmv.25948 - DOI - PMC - PubMed
    1. Cevik M., Bamford C., Ho A. (2020). COVID-19 pandemic - A focused review for clinicians. Clin. Microbiol. Infect. 10.1016/j.cmi.2020.04.023;. pii: S1198-743X(20)30231-7. - DOI - PMC - PubMed
    1. Chen Y., Colello J., Jarjour W., Zheng S. G. (2019). Cellular Metabolic Regulation in the Differentiation and Function of Regulatory T Cells. Cells. 21, 8. 10.3390/cells8020188 - DOI - PMC - PubMed